Delayed Generic Restasis Launch and Positive Clinical Data Support a Positive Allergan Outlook
We're maintaining our fair value estimate for wide-moat Allergan after making a few minor adjustments to our model. Near term, we've bumped up our revenue and earnings estimates for 2018 as a Restasis generic launch now looks likely for July, which is beyond our previous estimate for a launch earlier this quarter. Longer term, we're leaving most of our growth projections intact as recent Phase 2 data for Allergan's episodic migraine drug atogepant and Phase 3 data for sustained release bimatopro...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.